It seems like Teva will buy its way there. Cephalon ($3.0b), Proctor and Gamble ($1.5b), Ratiopharm ($2.0b), Taiyo($.5b) and Infarmasa ($1.8b) deals, the gross numbers should be somewhat easy.
I'm not sure anyone (except you) really gives a hoot about a 5 year forecast from 2010 anyway. Many things have changed or are changing that are not under their control.
Market Data 
Markets 
AI
